HST Global, Inc. (HSTC.OB)

Posted: Thu Dec 18, 2008 1:33 pm

HST Global, Inc. (HSTC.OB) is a development-stage biotechnology company committed to acquiring, developing and commercializing innovative products to enhance cancer care. The company determines to acquire proprietary rights to these products, fund their R&D, and bring the products to market. Since HST’s inception, they have focused their efforts and resources primarily on Salicinium, a clinical stage drug candidate, as well as raising capital and recruiting personnel.

The company’s focus is on in-licensing and further advancing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer. Although the cost of licensing drug candidates that have already completed initial clinical testing is significantly greater than those that clinical testing has not been completed, HST believes there is significantly less risk associated with the investment and continued development of clinical stage drugs since they are able to obtain an initial indication of the drug’s safety and efficacy before investing capital for the drug’s development.

HST utilizes a unique core concept in clinical drug development. Unlike many other pharmaceutical and biotech companies worldwide, HST is one of the few companies working to establish relationships and partnerships for the development of prescription drugs from natural sources to address current and emerging health crises.

HST holds to the belief that the synergy among the parts of a plant or substance from another natural source has significant value. These synergies are possibly one reason for the positive outcomes the company has encountered in pre-clinical and clinical investigations. HST takes this approach because they believe that plant co-factors, instead of a single chemical entity, will increase the overall safety and efficacy of the medicines that will potentially be produced through their efforts.

Posted: Fri Dec 19, 2008 2:20 pm

HST Global, Inc. (HSTC.OB) Strengthens Scientific Board with New Member

HST Global, Inc. announced earlier this month that Dr. Kyl Smith has joined its Scientific Board. Much of Dr. Smith’s visibility has been earned in the world of natural medicine. He is a noted researcher, inventor, lecturer, author and scientist, and is known as the inventor of Focus Factor®, the number-one selling brain support product in North America for the last seven years.

Dr. Kyl’s passion is teaching doctors how to use nutritional therapies to improve cognitive function. He has been featured on numerous radio and television programs across the country, is the author of the acclaimed Brighter Mind® book series and is a popular speaker providing Continuing Education programs for physicians.

With the help of a team of top scientists, Dr. Kyl filed a Health Claim Petition for Phosphatidylserine, which was approved by the Food and Drug Administration (FDA) in 2002. This is an unprecedented achievement represents the first Health Claim for cognitive function to be approved in the FDA’s history.

Ronald Howell, President and CEO of HST Global, Inc. stated, “There is a growing acceptance of integrative wellness and cancer treatments worldwide and HST is perfectly positioned to open our own brand of Integrative Wellness and Cancer Treatment Centers.”

Commenting on the announcement, Mr. Howell continued, “The addition of Dr. Kyl Smith to our Scientific Advisory Board will enable the company to strengthen our ability to address multiple challenges individuals face in the maintenance and treatment of numerous health conditions, and to provide Continuing Education modules and courses for physicians who wish to learn about scientifically validated integrative therapies.”

Posted: Tue Dec 23, 2008 11:04 am

HST Global, Inc. (HSTC.OB) has Big Plans for Next year

Alternative cancer treatments have been growing in acceptance worldwide, positioning HST Global perfectly to launch a wholly owned division focused on opening a new brand of Cancer Treatment Centers. While HST Global continues to look for in-licensing pre-clinical drug candidates, this strategy will allow the company to meet the needs of individuals that face cancer treatments.

Ronald Howell, President and CEO of HST Global, Inc. stated earlier in a press release, “There is a growing population of individuals experiencing the lack of available alternatives in treating late stage cancer. We have been working with a number of highly visible Physicians that are and have developed successful protocols that are meeting with success in the treatment of this population. As such, we will begin opening a privately branded chain of Cancer Treatment Centers strategically positioned around the world through a new wholly owned subsidiary.”

Mr. Howell continued, “The distribution channel established through our Cancer Treatment Centers will serve as a platform for implementing existing technologies and serve to identify appropriate communities for treatment with new and emerging drug candidates as they become available.”

Cancer is a world epidemic that does not discriminate. HST Global, Inc. has been involved with pre-clinical and proven drug candidates that have demonstrated high efficacy in the treatment of various cancers. The success and high efficacy recognized in these treatments has attracted a number of International partners that want to join the company’s vision and open Centers worldwide. Establishing a global chain of Cancer Treatment Centers will provide an immediate revenue stream to the company.

HST Global believes a number of events will take place in the coming year based on negotiations that have taken place. The Company intends to open its first corporate owned center in the first quarter 2009 and five partner centers worldwide in fiscal 2009. The annual estimated revenue stream from each individual clinic is estimated to be approximately $8-10 million dollars per year.

The Company will continue to search for revolutionary and novel products for the treatment of cancer and other life threatening diseases. Because of the unfortunate nature of cancer, the Company does not believe it will be affected by current or future economic conditions.

Posted: Mon Dec 29, 2008 12:32 pm

HST Global, Inc. (HSTC.OB) and EBITDA Capital are Focused on Attaining Success Together through Strategic Alliance

Earlier this year, HST Global announced that it contracted EBITDA Capital LLC of Newport Beach California and its group of associates to join HST-Global’s efforts in working toward an overall corporate strategy. The company also announced Former United States Congressman Bill Sarpalius, the President and CEO of Advantage Associates International, has been given the role of interfacing with the political community in Washington DC.

Mr. Sarpalius said, “We are excited to be in a position to raise the awareness of both the public and members of the government about HST’s treatment solution. The opportunity of bringing a treatment for late stage cancer is something which we all want to see expanded and made use of in the treatment community.”

Mr. Ron Howell, CEO and President of HST Global commented, “Through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment. We want to insure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice.”

“HST has worked to develop a complete strategy for the success of its program and treatment and is now moving toward a more public awareness platform. We believe that EBITDA and its associates, such as Advantage Associates, will help us get this done,” he continued.

Posted: Mon Jan 05, 2009 1:27 pm

HST Global, Inc. (HSTC.OB) is Making Great Progress with Treatment of Stage IV Breast Cancer

In 2008, HST Global, Inc. announced that it has met 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients. In the press release announcing results, Ronald Howell, President & CEO of HST Global, Inc., stated, “We are encouraged by these results and are looking forward to subjecting the study to more rigorous tests to support eventual commercialization.”

The company has obtained the rights to a pre-clinical outcome-based study using the pre-clinical drug trade named “Salicinium”. This natural substance derived from plants is both an oral and a parenteral active inhibitor of certain fermenting enzyme dynamics in the cancer cells. Clinical studies show that Salicinium alters malignant cell fermentation dynamics, blocks cell division (mitosis), and causes fermenting cancer cells to lose their ability to endure innate immune reactions.

The pre-clinical study proved Salicinium’s efficacy and safety, as well as freedom from adverse toxicities and adverse side-effects. The study concluded that Salicinium is a novel, homeopathic, immune boosting therapy that when used alone in breast cancer, isolated from other cancers, showed an overall response rate of 79% at 33 months.